B7-H3-Targeted RLT

About Mariana Oncology

Mariana Oncology is a private, preclinical-stage biotech subsidiary of Novartis, focused on developing targeted radioligand therapies (RLTs) for cancer. Its pipeline includes lead programs against DLL3 and B7-H3, targets associated with aggressive, hard-to-treat cancers with poor prognoses. The company leverages Novartis's expertise in the RLT field to design compounds for selective tumor targeting and rapid clearance, aiming to establish a new standard of care. As a fully integrated part of Novartis, it operates with strategic backing but faces competition in the rapidly evolving radiopharmaceutical sector.

Therapeutic Areas